Skip to content
2000
  1. Home
  2. A-Z Publications
  3. MicroRNA
  4. Fast Track Articles
  5. Fast Track Article
image of micro-RNA 451-a as a Circulating Biomarker for Neuroblastoma

Abstract

Introduction

Micro ribonucleic acids (miRNAs) are small non-coding RNAs that modulate the expression of various genes. They have an important role in cancer pathogenesis. Differential expression of multiple miRNAs have been used as potential diagnostic and prognostic markers.

Methods

Various cancers have lately been employed as therapeutic targets. This prospective study included untreated pediatric neuroblastoma (NB) patients. In the discovery phase, global miRNA profiling was done using next-generation sequencing (NGS) on biopsy tissue samples of NB patients. In this phase, the top expressing miRNA was identified and chosen for further validation as circulating miRNA in blood samples of a different set of NB patients by real-time polymerase chain reaction (PCR).

Results

Based on the read counts on the global miRNA profiling in the discovery phase, we found that the miRNA that consistently had high reads across the majority of the NB samples were miRNA 451-a, 19b-3p, 106b-5p, and 21-5p. Of these, we selected miRNA 451-a and 19-b for the validation phase of the study as they had consistent overexpression. In the validation phase, the expression of the circulating miRNA 451-a in the blood was found to be higher. The average value for the relative fold (RF) expression for miRNA 451-a was 1.52.

Conclusion

miRNA 451-a is overexpressed both in the cancer tissue and the blood of NB patients. It can serve as a potential diagnostic marker. Further studies can elucidate its role in the pathogenesis of NB and it can have utility as a therapeutic target.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/mirna/10.2174/0122115366361597250108075627
2025-01-10
2025-05-30

  • From This Site

    /content/journals/mirna/10.2174/0122115366361597250108075627
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Bartel D.P. MicroRNAs. Cell 2004 116 2 281 297 10.1016/S0092‑8674(04)00045‑5 14744438
    [Google Scholar]
  2. Mitchell P.S. Parkin R.K. Kroh E.M. Fritz B.R. Wyman S.K. Pogosova-Agadjanyan E.L. Peterson A. Noteboom J. O’Briant K.C. Allen A. Lin D.W. Urban N. Drescher C.W. Knudsen B.S. Stirewalt D.L. Gentleman R. Vessella R.L. Nelson P.S. Martin D.B. Tewari M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA 2008 105 30 10513 10518 10.1073/pnas.0804549105 18663219
    [Google Scholar]
  3. Schotte D. De Menezes R.X. Moqadam F.A. Khankahdani L.M. Lange-Turenhout E. Chen C. Pieters R. Den Boer M.L. MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia. Haematologica 2011 96 5 703 711 10.3324/haematol.2010.026138 21242186
    [Google Scholar]
  4. Leichter A.L. Sullivan M.J. Eccles M.R. Chatterjee A. MicroRNA expression patterns and signalling pathways in the development and progression of childhood solid tumours. Mol. Cancer 2017 16 1 15 10.1186/s12943‑017‑0584‑0 28103887
    [Google Scholar]
  5. Kakkar D. Mallick S. Ahmad A. Goswami A. Agarwala S. Gupta A.K. Sreenivas V. Bakhshi S. Devasenathipathy K. Mathur S. Jain D. Seth R. Iyer V.K. Differential expression of miRNA in histological subtype of Wilms tumor. Pediatr. Surg. Int. 2022 38 2 257 267 10.1007/s00383‑021‑05034‑6 34674019
    [Google Scholar]
  6. Fontana L. Fiori M.E. Albini S. Cifaldi L. Giovinazzi S. Forloni M. Boldrini R. Donfrancesco A. Federici V. Giacomini P. Peschle C. Fruci D. Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS One 2008 3 5 e2236 10.1371/journal.pone.0002236 18493594
    [Google Scholar]
  7. Wei J.S. Song Y.K. Durinck S. Chen Q-R. Cheuk A.T.C. Tsang P. Zhang Q. Thiele C.J. Slack A. Shohet J. Khan J. The MYCN oncogene is a direct target of miR-34a. Oncogene 2008 27 39 5204 5213 10.1038/onc.2008.154 18504438
    [Google Scholar]
  8. Parikh N.S. Howard S.C. Chantada G. Israels T. Khattab M. Alcasabas P. Lam C.G. Faulkner L. Park J.R. London W.B. Matthay K.K. SIOP‐PODC adapted risk stratification and treatment guidelines: Recommendations for neuroblastoma in low‐ and middle‐income settings. Pediatr. Blood Cancer 2015 62 8 1305 1316 10.1002/pbc.25501 25810263
    [Google Scholar]
  9. Li Z Li Y Fu J Li N Shen L. Clinical utility of microRNA-451 as diagnostic biomarker for human cancers. Biosci. Rep. 2019 39 1 BSR20180653 10.1042/BSR20180653 30509965
    [Google Scholar]
  10. Khordadmehr M. Jigari-Asl F. Ezzati H. Shahbazi R. Sadreddini S. Safaei S. Baradaran B. A comprehensive review on miR‐451: A promising cancer biomarker with therapeutic potential. J. Cell. Physiol. 2019 234 12 21716 21731 10.1002/jcp.28888 31140618
    [Google Scholar]
  11. Bai H. Wu S. miR-451: A Novel Biomarker and Potential Therapeutic Target for Cancer. OncoTargets Ther. 2019 12 11069 11082 10.2147/OTT.S230963 31908476
    [Google Scholar]
  12. Liu G. Xu Z. Hao D. MicroRNA-451 inhibits neuroblastoma proliferation, invasion and migration by targeting macrophage migration inhibitory factor. Mol. Med. Rep. 2016 13 3 2253 2260 10.3892/mmr.2016.4770 26783235
    [Google Scholar]
  13. Bian H.B. Pan X. Yang J.S. Wang Z.X. De W. Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549). J. Exp. Clin. Cancer Res. 2011 30 1 20 10.1186/1756‑9966‑30‑20 21329503
    [Google Scholar]
  14. Chen D. Huang J. Zhang K. Pan B. Chen J. De W. Wang R. Chen L. MicroRNA-451 induces epithelial–mesenchymal transition in docetaxel-resistant lung adenocarcinoma cells by targeting proto-oncogene c-Myc. Eur. J. Cancer 2014 50 17 3050 3067 10.1016/j.ejca.2014.09.008 25310895
    [Google Scholar]
  15. Jiang T. Ye L. Han Z. Liu Y. Yang Y. Peng Z. Fan J. miR-19b-3p promotes colon cancer proliferation and oxaliplatin-based chemoresistance by targeting SMAD4: validation by bioinformatics and experimental analyses. J. Exp. Clin. Cancer Res. 2017 36 1 131 10.1186/s13046‑017‑0602‑5 28938919
    [Google Scholar]
  16. Wei Y. Guo S. Tang J. Wen J. Wang H. Hu X. Gu Q. MicroRNA-19b-3p suppresses gastric cancer development by negatively regulating neuropilin-1. Cancer Cell Int. 2020 20 1 193 10.1186/s12935‑020‑01257‑0 32508529
    [Google Scholar]
  17. Roth S.A. Hald Ø.H. Fuchs S. Løkke C. Mikkola I. Flægstad T. Schulte J. Einvik C. MicroRNA-193b-3p represses neuroblastoma cell growth via downregulation of Cyclin D1, MCL-1 and MYCN. Oncotarget 2018 9 26 18160 18179 10.18632/oncotarget.24793 29719597
    [Google Scholar]
/content/journals/mirna/10.2174/0122115366361597250108075627
Loading
micro-RNA 451-a as a Circulating Biomarker for Neuroblastoma
Bentham Science Publishers ; https://doi.org/10.2174/0122115366361597250108075627
/content/journals/mirna/10.2174/0122115366361597250108075627
/content/journals/mirna/10.2174/0122115366361597250108075627
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: next-generation sequencing ; micro RNA ; neuroblastoma
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test